-
公开(公告)号：WO2021171230A1
公开(公告)日：2021-09-02
申请号：PCT/IB2021/051596
申请日：2021-02-26
发明人： SHARMA, Rajiv , AGARWAL, Sameer
IPC分类号： A01N47/36 , C07D213/34 , C07C381/10
摘要： The present invention relates to novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions in which interleukin 1β activity is implicated.
-
公开(公告)号：WO2021048809A1
公开(公告)日：2021-03-18
申请号：PCT/IB2020/058464
申请日：2020-09-11
发明人： SHARMA, Rajiv , AGARWAL, Sameer
IPC分类号： A61K31/125 , C07C381/10 , C07D213/70 , C07D213/76 , C07D295/096 , A61P29/00 , A61K31/40 , A61K31/4025 , A61K31/427 , A61K38/2013 , A61K38/21 , A61K45/06 , C07D207/08 , C07D207/48 , C07D405/04 , C07D417/06
摘要： The present invention relates to novel heterocyclic compounds of general formula (I) their tautomers, stereoisomers, enantiomers, pharmaceutically acceptable salts and pharmaceutical composition. The compounds of general formula (I) belongs to the family of NOD like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators and use of these novel inhibitor compounds in the treatment of disease or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) is implicated.
-
公开(公告)号：WO2022070048A1
公开(公告)日：2022-04-07
申请号：PCT/IB2021/058878
申请日：2021-09-29
发明人： SHARMA, Rajiv , AGARWAL, Sameer
IPC分类号： A61K31/454 , A61P11/00
摘要： The present invention relates to novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of papain-like protease (PLpro) modulators. The present invention thus relates to novel papain-like protease (PLpro) modulators and their use in the treatment of diseases or conditions in which SARS-CoV, SARS-CoV2 is implicated like severe acute respiratory syndrome (SARS), Middle east respiratory syndrome (MERS), Spanish flu, COVID19 (Coronavirus disease 2019), hepatitis C virus, chikungunya virus, influenza A virus, herpes simplex virus type 1 and Japanese encephalitis virus. Formula (I)
-
公开(公告)号：WO2013054338A1
公开(公告)日：2013-04-18
申请号：PCT/IN2012/000471
申请日：2012-07-04
发明人： AGARWAL, Sameer , JAIN, Mukul R , PATEL, Pankaj R
IPC分类号： C07D233/84 , C07D403/12 , C07D405/12 , C07D409/12 , A61K31/4178 , A61K31/4164 , A61P3/04
CPC分类号： C07D233/84 , C07D403/12 , C07D405/12 , C07D409/12
摘要： The present invention relates to compounds of the general Formula I their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, prodrugs, their N-oxide, metabolites, polymorphs, use of these compounds in medicine for treating diabetes (TGR5 modulators) and the intermediates involved in their preparation.
摘要翻译： 本发明涉及通式I的化合物，其药学上可接受的盐，药学上可接受的溶剂合物，对映异构体，非对映异构体，前药，其N-氧化物，代谢物，多晶型物，这些化合物在治疗糖尿病的药物中的用途（TGR5调节剂） 涉及中间体的制备。
-
公开(公告)号：WO2020148619A1
公开(公告)日：2020-07-23
申请号：PCT/IB2020/050216
申请日：2020-01-13
发明人： SHARMA, Rajiv , AGARWAL, Sameer
IPC分类号： C07D215/12 , C07D319/16 , C07D233/54 , C07C311/54 , C07D241/12 , C07D277/22
摘要： The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions in which interleukin 1β activity is implicated.
-
6.发明申请HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF DIABETES, OBESITY OR RELATED DISORDERS 审中-公开杂环化合物及其用于治疗糖尿病，肥胖或相关疾病的用途
公开(公告)号：WO2013164838A1
公开(公告)日：2013-11-07
申请号：PCT/IN2013/000130
申请日：2013-03-05
发明人： AGARWAL, Sameer , DESAI, Ranjit, C.
IPC分类号： C07D403/12 , C07D249/12 , A61K31/4196 , A61P3/10
CPC分类号： C07D403/12 , C07D249/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D487/04
摘要： The present invention discloses agonists of the G protein-coupled receptor TGR5, compositions comprising them, methods of making the compounds and compositions and using them, methods of making the compounds and compositions and using them for the treatment of diseases TGR5 mediates or is implicated in.
摘要翻译： 本发明公开了G蛋白偶联受体TGR5的激动剂，包含它们的组合物，制备化合物和组合物并使用它们的方法，制备化合物和组合物的方法以及用于治疗疾病TGR5介导或牵连的方法 。
-
7.发明申请
公开(公告)号：WO2013102929A1
公开(公告)日：2013-07-11
申请号：PCT/IN2012/000821
申请日：2012-12-17
发明人： AGARWAL, Sameer , DESAI, Ranjit, C.
IPC分类号： C07D403/12 , C07D233/84 , C07D401/12 , C07D409/12 , C07D487/04 , A61K31/4178 , A61P5/50
CPC分类号： C07D401/12 , C07D233/84 , C07D403/12 , C07D409/12 , C07D487/04
摘要： The present invention relates to compounds of the general Formula I their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, prodrugs, their N-oxide, metabolites, polymorphs, use of these compounds in medicine and the intermediates involved in their preparation.
摘要翻译： 本发明涉及通式I的化合物，其药学上可接受的盐，药学上可接受的溶剂合物，对映异构体，非对映异构体，前药，其N-氧化物，代谢物，多晶型物，这些化合物在医药中的用途以及参与其制备的中间体。
-
公开(公告)号：WO2021111351A1
公开(公告)日：2021-06-10
申请号：PCT/IB2020/061430
申请日：2020-12-03
发明人： SHARMA, Rajiv , AGARWAL, Sameer
IPC分类号： C07D521/00 , C07D403/12 , C07D407/14 , C07D401/14 , C07D413/12 , C07D417/12 , C07D487/00 , A61K31/64
摘要： The present invention relates to novel heterocyclic compounds of general formula (I) their tautomers, stereoisomers, enantiomers, pharmaceutically acceptable salts and pharmaceutical composition. The compounds of general formula (I) belongs to the family of NOD like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators and use of these novel inhibitor compounds in the treatment of disease or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin- 18 (IL-18) is implicated.
-
公开(公告)号：WO2019043610A1
公开(公告)日：2019-03-07
申请号：PCT/IB2018/056619
申请日：2018-08-30
发明人： SHARMA, Rajiv , IYER, Pravin , AGARWAL, Sameer
IPC分类号： C07D215/12 , C07D319/16 , C07D233/54 , C07C311/54 , C07D241/12 , C07D277/22 , C07D498/04 , C07D277/62 , C07D213/34 , C07D307/38 , A61P29/00 , A61P19/02
摘要： The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) is implicated.
-
公开(公告)号：WO2018225018A1
公开(公告)日：2018-12-13
申请号：PCT/IB2018/054134
申请日：2018-06-08
发明人： SHARMA, Rajiv , IYER, Pravin , AGARWAL, Sameer
IPC分类号： C07D213/76 , C07D319/18 , C07D231/38 , C07D333/34 , C07C381/10 , C07D295/096 , C07D305/08 , C07D213/70 , C07D307/64 , A61K31/4406 , A61P29/00 , C07D215/36
摘要： The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) is implicated.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.016 秒)
